Fischer Medical Ventures FY26: Scale Meeting Margin—So Far
General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1. At a Glance
Revenue scaled ₹309 crore in FY26—from ₹111 crore a year earlier. That is a 179% jump on the back of what management calls a ramp-up in preventive healthcare and continued radiology sales. But the story has a twist: the company posted net profit of ₹31 crore, yet operating cash burned ₹101 crore, while investing activity drained another ₹5 crore. The equity is now ₹385 crore, debt stands at ₹107 crore.
The market prices it at ₹34.83 per share—a P/E of 73.7x on reported earnings. That is a ceiling, not a sale.
Management claims margin expansion is structural, not a fluke. The order book is “strong,” but they won’t disclose numbers. Regulatory approvals for exports remain the gating factor. One eye stays on preventive healthcare scaling and the other on cash burn.
2. Introduction
Fischer Chemic rebranded to Fischer Medical Ventures in 2023. Once a trading house for laboratory chemicals, the company spent FY24–25 reverse-merging with Time Medical International, a MedTech platform spanning diagnostic imaging hardware (MRI, with plans for CT) and a preventive healthcare tech platform called FlynnCare.
The transformation isn’t hypothetical: FY25 saw revenue ₹111 crore, and FY26 pushed it to ₹309 crore. In the concall (Nov 2025 for Q2 FY26 results), management attributed growth to “scaling up… investing… marketing expenses,” which is code for they were in build mode.
Now comes the reckoning. Q4 FY26 (Mar 2026) reported sales of ₹97.73 crore, but the net profit turned negative at ₹-7.10 crore, while operating cash stayed deeply negative. Full-year PAT came to ₹31 crore, EPS ₹0.47. The company recommended a ₹0.05 dividend (11% payout ratio).
The next chapter depends on whether preventive healthcare can monetize at scale, radiology can land exports, and—above all—whether the cash burn normalizes.
3. Business Model: WTF Do They Even Do?
Fischer Medical presents itself as a “deep tech… both on hardware as well as software-as-medical device” MedTech platform. In plain speech: it builds MRI machines and a software platform for preventive screening.
Radiology segment (Time Medical perspective):
Core product: MICA & QUIN (1.5T MRI systems, helium and helium-free variants). Also PICA (open MR for musculoskeletal/spine).
The pitch: 20–35% cheaper capex than GE/Philips/Siemens; 10–15% lower opex. Government scan rates cap end-user pricing, so the customer’s payback window narrows.
Production capacity: 80 MRI per year (1 shift), ~150–160 with 2 shifts.
Pipeline: CT development “started,” interoperative MRI (iMRI—Medharanya program with Dr. Iype Cherian) “about to launch.”
Preventive Healthcare segment (FlynnCare):
Not a hardware manufacturer—the company integrates third-party devices (spirometry, fundus imaging, etc.) into a platform layer.
Platforms announced/rolling out: TB end-to-end (under India’s NTB program); Flynn OncoCare (cancer care, WHO-aligned); school preventive screening (kiosk-based, subscription model).
Revenue model: per-screening fees + subscriptions. H1 FY26 growth was “primarily driven by Preventive Healthcare.”
Capacity constraint: people + AI/server, not plant.
Geographic split (H1 FY26):
India: ~70%
Exports: ~30% (vs. 5–10% in FY25)
The two segments have opposite sales cycles: radiology is 6–12 months (capex, long conversion); preventive is shorter and “much more sustainable… repetitive business.”
The real roast: radiology requires manufacturing discipline and export licensing (both slow); preventive requires clinical adoption and subscription discipline (both unproven at scale). The company is trying both simultaneously. Good luck.
4. Financials Overview
Figures are consolidated, in ₹ crore.
Metric
FY25
FY26
YoY
Revenue
110.7
308.58
+178.5%
EBITDA*
2.33
43.09
+1,748%
PAT
1.47
31.02
+2,010%
EPS (₹)
0.02
0.47
+2,250%
*EBITDA estimated as Operating Profit + Depreciation; from quarterly breakdowns.
Quarter-by-quarter (FY26 Q-series, consolidated):
Quarter
Sales
Operating Profit
OPM
PAT
Q1 (Apr–Jun ’25)
23.44
4.26
18.17%
5.01
Q2 (Jul–Sep ’25)
86.31
16.22
18.79%
13.90
Q3 (Oct–Dec ’25)
101.10
21.57
21.34%
19.23
Q4 (Jan–Mar ’26)
97.73
1.00
1.02%
-7.10
What the management concall (Nov 2025) said:
The Q2 FY26 call is the only guidance snapshot available. Management attributed margin expansion to three drivers:
Operating leverage
Cost optimization
Richer mix: “growing share of export sales and preventive healthcare solutions, which carry higher margins”
Management explicitly avoided revenue/margin guidance and framed growth expectations as “in line of the macro growth” (~15–20% cited for sector).
What happened in Q4?
Revenue stayed high at ₹97.73 crore. But operating profit collapsed to ₹1 crore, and the company posted a ₹-7.10 crore loss. This suggests either one-time charges, a drop in mix quality, or both. The full-year loss was absorbed into the 9-month profit, so FY-full still landed ₹31 crore PAT.
5. Market Expectations & Historical Multiples
This section describes how the market is currently pricing the
